http://www.istavision.com/
http://finance.yahoo.com/q/ks?s=ISTA
ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye in the United States. The company offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. Its developing products include Bepotastine ophthalmic solution for allergic conjunctivitis; T-Pred, a Phase III clinical trial product candidate for the treatment of steroid-responsive inflammatory ocular conditions; Ecabet Sodium, a Phase IIb clinical trial product, for the treatment of dry eye syndrome; and Bepotastine nasal for the treatment of allergic rhinitis. The company's products developing products also include a steroid product candidate to treat ocular inflammation; iganidipine to enhance ocular nerve blood flow; and a formulation of latanoprost for the treatment of glaucoma. It sells its products primarily to drug wholesalers, retailers, and distributors, including chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. ISTA Pharmaceuticals was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. The company was founded in 1992 and is headquartered in Irvine, California.
